Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER versus HEPATASOL 8.
Head-to-head clinical analysis: AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 20 W CALCIUM IN PLASTIC CONTAINER versus HEPATASOL 8.
AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER vs HEPATASOL 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis, counteract negative nitrogen balance, and maintain muscle mass. Dextrose supplies calories for energy metabolism, and electrolytes correct or prevent imbalances.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
1-2 L/day intravenously, infused at a rate of 1-2 mL/kg/hour (50-100 mL/hour) for a 70 kg adult, adjusted based on nitrogen and caloric needs.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
None Documented
None Documented
Variable; amino acids have half-lives of minutes to hours depending on metabolic demand and renal function. Dextrose has a half-life of 15-20 minutes under normal conditions. In renal impairment, half-life of amino acid byproducts may prolong.
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Urea (from amino acid metabolism) is excreted renally. Electrolytes and dextrose metabolites are eliminated via renal and respiratory routes. No significant biliary/fecal elimination.
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution